市場調查報告書
商品編碼
1368717
旅行疫苗市場規模- 按成分(單一和組合疫苗)、疾病類型(甲型和乙型肝炎、流感、百白破、黃熱病、腦膜炎球菌、傷寒、狂犬病、麻疹和腮腺炎)、應用、全球預測,2023-2032年Travel Vaccines Market Size - By Composition (Mono & Combination Vaccines), Disease Type (Hepatitis A & B, Influenza, DPT, Yellow Fever, Meningococcal, Typhoid, Rabies, Measles & Mumps), Application, Global Forecast, 2023-2032 |
受麻疹和登革熱等幾種新傳染病的湧入和現有傳染病死灰復燃的推動,旅行疫苗市場規模從 2023 年到 2032 年的年複合成長率預計將達到 9.7%。根據疾病管制與預防中心的數據,2021 年麻疹估計導致 128,000 人死亡,其中大部分是兒童。
旨在改進現有旅行疫苗和開發新疫苗的持續研發活動和投資也將有助於產業成長。舉例來說,2023年5月,巴伐利亞北歐公司投資2.74億美元收購Emergent BioSolutions的旅遊疫苗組合,以加強其研發和製造能力。人們越來越關注創造更方便的單劑量疫苗以提供更廣泛的保護,這也將增加產品的採用。
整個旅行疫苗產業根據成分、疾病類型、應用和地區進行細分。
就成分而言,2023-2032年組合旅行疫苗的需求可能會出現可觀的年複合成長率。組合疫苗用於簡化疫苗接種過程並提高旅行者的依從性。這些疫苗對於在不同地區有接觸多種傳染病風險的旅客特別有益,因為它們限制了多次疫苗接種的需要,同時提供了對多種疾病的保護。消費者越來越傾向於減少所需的注射和注射次數,這也將有利於產品的吸收。
就疾病類型而言,預計到2032 年,乙型肝炎細分市場的旅遊疫苗市場將實現顯著的年複合成長率。隨著醫療旅遊業的快速成長,醫療機構越來越重視患者和醫療遊客對乙型肝炎疫苗的需求。限制感染傳播。乙型肝炎盛行率較高(主要在非洲和亞洲),加上與工作相關的旅行率上升,將推動該細分市場的成長。根據世界衛生組織的數據,2022 年將有近 9,100 萬非洲人感染B型或C型肝炎。
從地區來看,由於中產階級人口的快速成長和對國際旅行的偏好不斷增加,預計到 2032 年,亞太地區旅行疫苗市場規模將出現可觀的年複合成長率。該地區多個政府正在不斷審查和更新與旅遊疫苗相關的法規,例如入境要求和疫苗接種證明。醫療保健組織對旅遊疫苗重要性的日益重視也將有利於區域市場的擴張。
Travel Vaccines Market size is poised to record 9.7% CAGR from 2023-2032, driven by the influx of several new infectious diseases and the resurgence of existing ones, including measles and dengue. As per the Centers for Disease Control and Prevention, measles killed an estimated 128,000 people, mostly children in 2021.
The ongoing R&D activities and investments aimed at improving the existing travel vaccines and developing new vaccines will also assist the industry growth. To cite an instance, in May 2023, Bavarian Nordic invested $274M to acquire travel vaccine portfolio of Emergent BioSolutions in a bid to strengthen its R&D and manufacturing capabilities. The growing focus on the creation of more convenient, single-dose vaccines to offer broader protection will also add to the product adoption.
The overall travel vaccines industry is segmented based on composition, disease type, application, and region.
In terms of composition, the demand for combination travel vaccines may record appreciable CAGR from 2023-2032. Combination vaccines are used for simplifying the vaccination process and enhance compliance among travelers. These vaccines are especially beneficial for travelers at risk of exposure to several infectious diseases in different regions as they limit the need for multiple vaccinations while rendering protection against multiple diseases. The rising consumer preference for reducing the number of required injections and shots will also prove favorable for the product uptake.
With respect to disease type, the travel vaccines market from the hepatitis B segment is expected to garner significant CAGR through 2032. With the rapid growth in medical tourism, healthcare facilities are highlighting the requirement for hepatitis B vaccines for patients as well as medical tourists to limit the infection transmission. The higher prevalence of hepatitis B, mainly in Africa and Asia along with the rising rate of work-related travel will drive the segment growth. As per the WHO, nearly 91 million Africans were infected with Hepatitis B or C in 2022.
Regionally, APAC travel vaccines market size is projected to record appreciable CAGR through 2032 due to the rapid growth of the middle-class population and the rising preference for international travel. Several governments in the region are constantly reviewing and updating regulations related to travel vaccines, such as entry requirements and vaccination certificates. The surging emphasis laid by healthcare organizations about the importance of travel vaccinations will also prove favorable for the regional market expansion.